$119.20
1.30% yesterday
Nasdaq, Aug 19, 10:13 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Target price 2025 - Analyst rating & recommendation

Jazz Pharmaceuticals Plc Classifications & Recommendation:

Buy
92%
Hold
8%

Jazz Pharmaceuticals Plc Price Target

Target Price $181.77
Price $119.20
Potential
Number of Estimates 20
20 Analysts have issued a price target Jazz Pharmaceuticals Plc 2026 . The average Jazz Pharmaceuticals Plc target price is $181.77. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 25 analysts: 23 Analysts recommend Jazz Pharmaceuticals Plc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Jazz Pharmaceuticals Plc stock has an average upside potential 2026 of . Most analysts recommend the Jazz Pharmaceuticals Plc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 4.07 4.32
6.12% 6.10%
EBITDA Margin 33.27% 18.22%
0.84% 45.24%
Net Margin 13.77% 6.82%
27.23% 50.46%

22 Analysts have issued a sales forecast Jazz Pharmaceuticals Plc 2025 . The average Jazz Pharmaceuticals Plc sales estimate is

$4.3b
Unlock
. This is
5.64% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.6b 12.05%
Unlock
, the lowest is
$4.0b 2.39%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $4.1b 6.12%
2025
$4.3b 6.10%
Unlock
2026
$4.5b 5.07%
Unlock
2027
$4.8b 6.77%
Unlock
2028
$5.2b 7.78%
Unlock
2029
$5.5b 6.00%
Unlock
2030
$5.5b 1.08%
Unlock
2031
$5.3b 2.36%
Unlock
2032
$5.4b 1.44%
Unlock

12 Analysts have issued an Jazz Pharmaceuticals Plc EBITDA forecast 2025. The average Jazz Pharmaceuticals Plc EBITDA estimate is

$787m
Unlock
. This is
36.92% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$842m 32.45%
Unlock
, the lowest is
$731m 41.39%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $1.4b 5.23%
2025
$787m 41.90%
Unlock
2026
$1.9b 146.76%
Unlock
2027
$2.1b 6.39%
Unlock
2028
$2.4b 15.59%
Unlock
2029
$2.6b 7.29%
Unlock
2030
$2.5b 3.28%
Unlock
2031
$2.1b 13.48%
Unlock
2032
$2.1b 3.22%
Unlock

EBITDA Margin

2024 33.27% 0.84%
2025
18.22% 45.24%
Unlock
2026
42.79% 134.85%
Unlock
2027
42.64% 0.35%
Unlock
2028
45.73% 7.25%
Unlock
2029
46.29% 1.22%
Unlock
2030
45.26% 2.23%
Unlock
2031
40.10% 11.40%
Unlock
2032
38.26% 4.59%
Unlock

21 Jazz Pharmaceuticals Plc Analysts have issued a net profit forecast 2025. The average Jazz Pharmaceuticals Plc net profit estimate is

$295m
Unlock
. This is
172.76% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$350m 186.50%
Unlock
, the lowest is
$184m 145.36%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $560m 35.02%
2025
$295m 47.41%
Unlock
2026
$1.3b 353.20%
Unlock
2027
$1.4b 8.09%
Unlock
2028
$1.5b 6.45%
Unlock
2029
$1.8b 15.44%
Unlock
2030
$1.7b 6.75%
Unlock
2031
$1.3b 22.53%
Unlock
2032
$1.4b 12.04%
Unlock

Net Margin

2024 13.77% 27.23%
2025
6.82% 50.46%
Unlock
2026
29.43% 331.52%
Unlock
2027
29.80% 1.26%
Unlock
2028
29.43% 1.24%
Unlock
2029
32.05% 8.90%
Unlock
2030
30.21% 5.74%
Unlock
2031
23.97% 20.66%
Unlock
2032
26.47% 10.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 8.48 4.86
47.48% 42.69%
P/E 24.22
EV/Sales 2.51

21 Analysts have issued a Jazz Pharmaceuticals Plc forecast for earnings per share. The average Jazz Pharmaceuticals Plc EPS is

$4.86
Unlock
. This is
173.52% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$5.78 187.44%
Unlock
, the lowest is
$3.03 145.84%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $8.48 47.48%
2025
$4.86 42.69%
Unlock
2026
$22.02 353.09%
Unlock
2027
$23.80 8.08%
Unlock
2028
$25.33 6.43%
Unlock
2029
$29.24 15.44%
Unlock
2030
$27.27 6.74%
Unlock
2031
$21.12 22.55%
Unlock
2032
$23.67 12.07%
Unlock

P/E ratio

Current -17.80 190.97%
2025
24.22 236.05%
Unlock
2026
5.34 77.95%
Unlock
2027
4.94 7.49%
Unlock
2028
4.65 5.87%
Unlock
2029
4.02 13.55%
Unlock
2030
4.32 7.46%
Unlock
2031
5.57 28.94%
Unlock
2032
4.97 10.77%
Unlock

Based on analysts' sales estimates for 2025, the Jazz Pharmaceuticals Plc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.65 2.21%
2025
2.51 5.32%
Unlock
2026
2.39 4.83%
Unlock
2027
2.24 6.34%
Unlock
2028
2.08 7.22%
Unlock
2029
1.96 5.66%
Unlock
2030
1.98 1.10%
Unlock
2031
2.03 2.41%
Unlock
2032
2.00 1.42%
Unlock

P/S ratio

Current 1.75 0.34%
2025
1.65 5.34%
Unlock
2026
1.57 4.83%
Unlock
2027
1.47 6.34%
Unlock
2028
1.37 7.22%
Unlock
2029
1.29 5.66%
Unlock
2030
1.30 1.10%
Unlock
2031
1.34 2.42%
Unlock
2032
1.32 1.42%
Unlock

Current Jazz Pharmaceuticals Plc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Morgan Stanley
Locked
Locked
Locked Aug 06 2025
Morgan Stanley
Locked
Locked
Locked Jul 22 2025
Needham
Locked
Locked
Locked Jun 11 2025
Needham
Locked
Locked
Locked Jun 03 2025
Baird
Locked
Locked
Locked May 07 2025
Needham
Locked
Locked
Locked May 07 2025
Morgan Stanley
Locked
Locked
Locked May 07 2025
Analyst Rating Date
Locked
Morgan Stanley:
Locked
Locked
Aug 06 2025
Locked
Morgan Stanley:
Locked
Locked
Jul 22 2025
Locked
Needham:
Locked
Locked
Jun 11 2025
Locked
Needham:
Locked
Locked
Jun 03 2025
Locked
Baird:
Locked
Locked
May 07 2025
Locked
Needham:
Locked
Locked
May 07 2025
Locked
Morgan Stanley:
Locked
Locked
May 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today